Академический Документы
Профессиональный Документы
Культура Документы
BIPOLAR DISORDERS
Review Article
235
Li et al.
disorders (1113). Furthermore, case reports and
retrospective studies suggest that clozapine may be
particularly eective in the treatment of medication-resistant unipolar depression and bipolar disorder (BD); some even suggested it is more
eective than it is for schizophrenia (12, 1416).
Compared with unipolar depression, BD is a
more serious type of mood disorder. BD is a recurrent, potentially disabling, sometimes even fatal
psychiatric illness (1719), and the estimated lifetime prevalence of various types of BD is over
2.0% (20, 21). BD is often associated with high levels of unfavorable outcomes or treatment resistance (2224). In contrast to schizophrenia,
denitions of treatment-resistant bipolar disorder
(TRBD) vary greatly (17, 2527). However, a failure to respond to at least two trials of dissimilar
treatments, involving an adequate dose and duration, could serve as a conservative denition
(2831).
Although mood disorder was traditionally considered a rather rare condition in China, recently
conducted epidemiological studies in the country
showed that it is one of the common mental disorders (32, 33), with a one-month prevalence of 6.1%
(32). Unlike other countries, clozapine has been
widely used for BD in China despite not having
been approved for mood disorders (3436), and it
is indeed one of the most commonly used antipsychotics in the treatment of BD (34, 37, 38). Some
psychiatrists even preferred it as a rst-line treatment for mania (3840). Similar to ndings from
studies in Western countries, RCTs showed that
clozapine was an eective add-on treatment to antidepressants for treatment-resistant depression
(41). Clozapine was also eective for treatmentresistant mania in a case report (42) and an RCT
(43).
Clozapine is a drug of choice for TRBD in
China but the evidence for its use in Western countries remains sparse, and the studies are limited to
case reports (44), open-label trials (11), and only
one RCT with fewer than 20 patients in each group
(45). As China has the largest population on clozapine (4648), the Chinese experience and studies
may be of keen interest to Western psychiatrists
(49). So far, no exhaustive systematic review on
clozapine for TRBD has been published.
The primary aim of this review was to evaluate
the ecacy and safety of clozapine for TRBD. As
previously mentioned, in addition to international
databases, we also included Chinese databases that
are not usually reviewed in articles written by
Western psychiatrists. Particular attention was
paid to safety and tolerability, as the potentially
severe adverse drug reactions (ADRs) associated
236
237
238
25 manic with
BD or SAD
5 children or
adolescents
with BD
17 mood
disorders
25 acutely manic
22 active manic
34 psychotic BD,
31 SCH, 26 SAD,
bipolar type
37 psychotic BD,
34 SCH, 30 SAD,
bipolar type
Kimmel et al.
1994 (62)
Kowatch et al.
1995 (65)
Calabrese et al.
1996 (44)
Green et al.
2000 (63)
Ciapparelli et al.
2000 (59)
16.1
CLZ
CLZ flexible
doses
2 ACs + APs
CLZ flexible
doses
CLZ
12
48
24
CLZ (75225) +
Li
CLZ (494)
13
18.7
3660
Duration
(months)
CLZ
CLZ
CLZ (50500) +
ACs
Treatments
(mg/day)
Combinations of Li,
ACs, APs, and ECT;
or had tardive dyskinesia
Li, ACs, and APs,
intolerable ADRs, or both
Undefined
Standard
treatments
including ACs
Resistance definition
(failure of)
72% (18/25) improved on the YMRS and 32% (8/25) improved on the BPRS.
The patients with BD as compared to the patients with SAD, and the nonrapid cycling patients as compared to rapid cyclers, had significantly
greater improvement in total BPRS score
57% (13/22) improved on the BPRS, 57% (12/22) on the YMRS, and 39%
(8/22) on the CGI, and 77% (17/22) experienced at least a 20%
reduction on all three scales
All patients showed significant improvement 24 months from intake (based
on BPRS and CGI). The presence of suicidal ideation at intake predicted
greater improvement at endpoint
Patients with SAD and BD show greater clinical improvement than those
with SCH. Patients with BD had the shortest time to response and the
highest psychosocial and occupational functioning levels (based
on BPRS, CGI, and GAF)
Three patients demonstrated striking mood stabilization and returned to
previous levels of functioning (based on BPRS and HDRS). Five patients
had moderate improvement in mood stabilization and functioning (based
on BPRS and HDRS), and one patient showed a minimal response
There was a 42% decrease in the CGI. Treatment was for aggressive
behavior and psychotic symptoms
Main findings
AC = anticonvulsant; ADR = adverse drug reaction; AP = antipsychotic; BD = bipolar disorder; BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impression; CLZ = clozapine;
ECT = electroconvulsive therapy; GAF = Global Assessment of Functioning; HDRS = Hamilton Depression Rating Scale; Li = lithium; SAD = schizoaffective disorder; SCH = schizophrenia;
UD = unipolar depression; YMRS = Young Mania Rating Scale.
Fehr et al.
2005 (64)
Ciapparelli et al.
2003 (60)
9 BD
52 BD, 81 SAD,
14 UD, 40 SCH
Banov et al.
1994 (11)
Zarate et al.
1995 (61)
7 with dysphoric
mania
Subjects
Suppes et al.
1992 (16)
Study
Li et al.
Study
Calabrese et al.
1991 (74)
Suppes et al.
1994 (15)
Subjects
2 RC BD
3 RC BD
Antonacci &
Swartz
1995 (70)
Poyurovsky &
Weizman
1996 (71)
Lancon & Llorca
1996 (75)
Mahmood et al.
1997 (72)
Chanpattana
2000 (73)
Xu 2003 (42)
4 euphoric
mania
Chen et al.
2005 (76)
Vijay Sagar
2005 (79)
Quante et al.
2007 (119)
Gupta
2009 (78)
Bastiampillai
et al. 2010 (77)
Bennedetti et al.
2010 (29)
Age, gender
47 years, F
48 years, F
43 years, F
25 years, F
45 years, F
Unavailable
Resistance
definition
(failure of)
Treatments
(mg/day)
Duration
(months)
Main findings
AC + AP
CLZ (250350)
1.53.5
Remission
AP + AC
CLZ (150400) + Li
1220
2 remission,
1 response
Standard
treatments + AC
CLZ
Enhanced functioning
and insight
2 mania
24 years, M
41 years, F
AP + AC
CLZ (250350)
+ ECT
Remission
1 RC BD
42 years, F
CLZ
Successfully treated
3 mania
Unavailable
Conventional
therapy
AP + AC
CLZ
Successfully treated
1 mania
26 years, M
18
Complete remission
1 mania
40 years, F
Conventional
treatment
AP + AC
Remarkably effective
1 RC BD
38 years, F
36
Complete remission
1 juvenileonset BD
3 BD, 2 UD
18 years, F
CLZ (600) +
Li (1,500) +
CBZ (600)
CLZ (350) +
TPR (300)
CLZ (200)
24
Remission
1 BD
28 years, M
1 RC BD
52 years, F
7 SAD and
psychotic BD
Not provided
Various biological
therapies
AC combinations
Medications +
ECT
Standard AC
12
CLZ (350)
66
Standard APs +
ACs
Treatment
resistant
CLZ (150) +
LTG (100)
Aripiprazole (6.8) +
CLZ (293)
60
Remission
AC = anticonvulsant; AP = antipsychotic; BD = bipolar disorder; CBZ = carbamazepine; CLZ = clozapine; ECT = electroconvulsive
therapy; F = female; Li = lithium; LTG = lamotrigine; M = male; RC = rapid cycling; SAD = schizoaffective disorder; TPR = topiramate;
UD = unipolar depression.
239
Li et al.
protocols of included RCTs. If the protocol was
available, outcomes in the protocol and in the
published report were compared. If the protocol
was not available, outcomes listed in the methods
section of the trial report were compared with the
actually reported results (54).
Grading recommendations
We used the grading of recommendations assessment, development, and evaluation (GRADE) system to rate the quality of evidence and strength of
recommendations of this systematic review following the guidelines of the Cochrane Collaboration.
GRADE included systematic assessments of all
included trials across six main domains for each
outcome: limitations of the study design and execution, inconsistency, indirectness, imprecision of
results, publication bias, and large treatment eect.
Accordingly, we graded the recommendation for
the outcome measure of clozapine for BD as very
low, low, moderate, or high (Table 5).
Results
Table 5. Grading of recommendations assessment, development, and evaluation system (GRADE) analysis: quality assessment of clozapine for
treatment-resistant bipolar disorder
Critical outcome
Participants
(studies)
Open studies
CGI score
236 (5)
BPRS score
248 (5)
YMRS score
47 (2)
Social functioning
304 (4)
Hospital days/year
377 (2)
Mean no. of admissions 377 (2)
Randomized clinical trials
BPRS score
109 (2)
HDRS score
109 (2)
Risk of
bias
Overall
quality
of evidenced
Inconsistency
Indirectness
Imprecision
Public bias
Large
effect
Seriousa
No
No
Seriousb
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Undetected
Undetected
Undetected
Undetected
Undetected
Undetected
No
No
No
No
No
No
Very low
Low
Low
Very low
Low
Low
Noc
Noc
No
No
No
No
No
No
Undetected
Undetected
No
No
Moderate
Moderate
BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impression; HDRS = Hamilton Depression Rating Scale; YMRS = Young
Mania Rating Scale.
a
Incomplete accounting of patients and outcome events.
b
Relatively few patients (n 10).
c
Lack of allocation concealment.
d
The quality of evidence was rated using the GRADE Working Group system. High quality indicates that further research is very unlikely
to change our confidence in the estimate of effect but none of the studies reached that level. Moderate quality indicates that further
research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality indicates that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change
the estimate. Very low quality indicates that we are very uncertain about the estimate.
240
Metabolic system
Endocrine system
Cardiovascular
system
Digestive system
Nervous system
Leukopenia
Decreases in white
blood cell count
Agranulocytosis
Weight gain
Weight loss
Hyperlipidemia
Increased appetite
Diabetes type 2
Sialorrhea
Sweating
Dry mouth
Influenza-like syndrome
Abnormal EEG
Orthostatic hypertension
Tachycardia
Orthostatic hypotension
Constipation
Diarrhea
Nausea/vomiting
Postprandial regurgitation
Ileus
Sedation
Body ache and pain
Dizziness
Sleep cycle inversion
Transient fever
Urinary incontinence
Seizure
Tremors
Fatigue
Neuroleptic malignant
syndrome
Bradykinesia
Enuresis
Mental confusion
n (% of
797 total)
14 (1.7)
6 (0.8)
2 (0.3)
31 (4.0)
1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)
42 (5.2)
4 (0.5)
1 (0.1)
1 (0.1)
6 (0.8)
6 (0.8)
6 (0.8)
2 (0.2)
40 (5.0)
8 (1.1)
5 (0.6)
1 (0.1)
1 (0.1)
98 (12.2)
15 (1.8)
11 (1.4)
7 (1.1)
8 (0.9)
6 (0.8)
4 (0.5)
2 (0.2)
2 (0.2)
1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)
241
Li et al.
addition, they also found that BD patients showed
greater clinical improvement than those with
schizophrenia in the long-term follow-up (11, 60).
Clozapine ADRs in TRBD
While many patients with BD respond well to conventional medications (including antidepressants,
mood stabilizers and antipsychotics), a substantial
proportion do not achieve a satisfactory response
(6769). This systematic review showed that clozapine may be an ecacious therapy for TRBD.
First, RCTs showed that: (i) clozapine add-on
treatment was superior to treatment as usual in
mania, and (ii) clozapine plus lithium was better
than clozapine plus valproate in rapid cycling BD.
Secondly, retrospective studies of clozapine for
TRBD indicated that the total number and duration of hospitalizations and the number of psychotropic co-medications were signicantly reduced
during clozapine treatment. Thirdly, in open-label
prospective studies, patients treated with clozapine
demonstrated a signicant decrease in the YMRS,
242
243
Li et al.
leads other than the use of clozapine for TRBD
mania, which is comparable to our analysis. Their
review was limited by: (i) inclusion of only two
clozapine trials (44, 45), (ii) lack of report on clozapine ADRs, and (iii) lack of inclusion of Chinese
studies which include larger numbers of patients.
Gitlin (116) conducted a review on this topic.
That review indicated that combining multiple
agents was the most commonly used clinical strategy for TRBD; an approach that may be eective
for treatment-resistant patients included high-dose
thyroid augmentation, clozapine, calcium channel
blockers, and electroconvulsive therapy, which is
consistent with our ndings. However, only three
studies of clozapine treatment were included (45,
60, 64), and none of the Chinese studies were
included. Similarly, there was no safety analysis or
data synthesis.
Frye et al. (117) reviewed the use of atypical
antipsychotics in the treatment of BD, focusing
on clozapine as the prototypical agent. That
review indicated that the early clinical experience
of clozapine as a potential mood stabilizer suggested greater anti-manic than antidepressant
properties. However, that review only included
some trials conducted before 1998, which
excluded most trials of clozapine for TRBD.
Similarly, there was no safety analysis or data
synthesis in that analysis.
Conclusions
244
Disclosures
The authors of this paper report no nancial relationship with
commercial interests within the last three years.
Author contributions
X-BL and Y-LT contributed equally to the review of the articles and to the writing of the rst draft. C-YW and JdL contributed by improving the rst and later drafts. All authors
contributed to and approved the nal manuscript.
References
1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for
the treatment-resistant schizophrenic: a double-blind
comparison with chlorpromazine. Arch Gen Psychiatry
1988; 45: 789796.
2. Marder SR, Van Putten T. Who should receive clozapine? Arch Gen Psychiatry 1988; 45: 865867.
3. Meltzer HY. Dimensions of outcome with clozapine. Br
J Psychiatry Suppl 1992; 17: 4653.
4. Meltzer HY, Okayli G. Reduction of suicidality during
clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benet assessment. Am J Psychiatry
1995; 152: 183190.
5. Asenjo Lobos C, Komossa K, Rummel-Kluge C et al.
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Library 2010; CD006633.
6. Leucht S, Cipriani A, Spineli L et al. Comparative ecacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet
2013; 382: 951962.
7. Attard A, Taylor DM. Comparative eectiveness of
atypical antipsychotics in schizophrenia. CNS Drugs
2012; 26: 491508.
8. Owen R Jr, Beake B, Marby D, Dessain E, Cole J.
Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989; 25: 253.
9. Naber D, Hippius H. The European experience with use
of clozapine. Hosp Community Psychiatry 1990; 41:
886890.
30. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215236.
31. Sharm V, Khan M, Corpse C. Role of lamotrigine in the
management of treatment-resistant bipolar II depression:
a chart review. J Aect Disord 2008; 111: 100105.
32. Phillips MR, Zhang J, Shi Q et al. Prevalence, treatment,
and associated disability of mental disorders in four
provinces in China during 200105: an epidemiological
survey. Lancet 2009; 373: 20412053.
33. Tsai S-Y, Chen C-C, Yeh E-K. Alcohol problems and
long-term psychosocial outcome in Chinese patients with
bipolar disorder. J Aect Disord 1997; 46: 143150.
34. Si TM, Shu L, Yu X et al. A cross-sectional study on
treatment patterns of bipolar disorders in China in 2006.
Chin J Psychiatry 2012; 45: 2934.
35. Chen XL, Xing BP, Zhang YQ, Jin WD. Atypical antipsychotics in the treatment of elder patients with mania.
Herald Med 2008; 27: 672673.
36. Fan ZG, Chen JM, Lu GH. Comparison analysis of
clozapine treatment for 54 cases with mania Chin. J Neurol 1994; 39: 202.
37. Liu YQ, Zhun FY, Yang LZ, Wang RJ, Chen CM. Clinical treatment analysis of 528 cases of aective disorders
patients. Chin J Pharmacoepidemiol 1997; 5: 158161.
38. Wang GY, Dong YM. The investigation and analysis of
outpatient drug use in psychiatry. Chin J Modern Drug
Application 2007; 1: 44.
39. Liu TB, Gao H, Shen QJ. Clozapine combined with lithium carbonate in the treatment of acute mania. J Clin
Psychiatry 2000; 10: 350351.
40. Zhang L, Chen JD. A double-blind study of clozapine
combined with lithium carbonate. J Psychiatry 2002; 15:
4041.
41. Yan JX. A double-blind clinical trial of add-on clozapine
in the treatment of treatment-resistant depression. Clin J
Psychol Med 2001; 11: 170171.
42. Xu XH. One case of treatment-resistant twin mania.
J Clin Psychosom Dis 2003; 9: 26.
43. Tan J. The ecacy and safety of lithium and low-dose
clozapine treatment for refractory bipolar. Youjiang
Med 2010; 38: 150151.
44. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry
1996; 153: 759764.
45. Suppes T, Webb A, Paul B, Carmody T, Kraemer H,
Rush AJ. Clinical outcome in a randomized 1-year trial
of clozapine versus treatment as usual for patients with
treatment-resistant illness and a history of mania. Am J
Psychiatry 1999; 156: 11641169.
46. Si TM, Shu L, Yu X et al. Antipsychotic drug patterns
of schizophrenia in China: a cross-sectioned study. Chin
J Psychiatry 2004; 37: 152155.
47. Zhang GP, Wang CY. The one-day survey on psychotropic drug use in 788 psychotic inpatients in Beijing Anding Hospital. Chin J Clin Pharmacol 2001; 17: 287289.
48. Luo RL, Chen Q. Investigation and analysis of psychotropic in 296 inpatients in one day. J Chin People Health
2009; 21: 17551756.
49. Tang YL, Mao PX, Jiang F et al. Clozapine in China.
Pharmacopsychiatry 2008; 41: 19.
50. Moher D, Liberati A, Tetzla J, Altman DG. Preferred
reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med 2009;
151: 264269.
51. Nielsen J, Kane JM, Correll CU. Real-world eectiveness of clozapine in patients with bipolar disorder: results
245
Li et al.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
246
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
247